György Enyedi (geographer)

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Retrieved on: 
木曜日, 11月 2, 2023
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Novartis Institute for Tropical Diseases, Research, NSCLC, Acute myeloid leukemia, IMGN, Food, PIN, Biomedical Research, ImmunoGen, European Medicines Agency, Doctor of Philosophy, Medicine, Capital expenditure, New Drug Application, Takeda Pharmaceutical Company, Marketing, BPDCN, ESGO, US Foods, Azacitidine, European Society of Gynaecological Oncology, EMA, ORR, NDA, Safety, Cancer, György Enyedi (geographer), Patient, National Medical Products Administration, Eli Lilly and Company, MAA, Congress, Mirvetuximab soravtansine, Blastic plasmacytoid dendritic cell neoplasm, ASH, Growth, ADC, Spacecraft, FDA, NMPA, PROC, University Clinical Centre in Gdańsk, Society, Senior, Inc., Huadong Medicine, AML, PARP, Vaccine, Pharmaceutical industry, Dietary supplement, Takeda

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
  • We also continued to monitor the NSCLC cohort with IMGC936 and advanced dose escalation with IMGN151, our second-generation ADC targeting FRα.
  • Selling, general and administrative expenses were $37.7 million for the quarter ended September 30, 2023 compared to $33.6 million for the quarter ended September 30, 2022.
  • Capital expenditures were $1.6 million and $1.1 million for the first nine months of 2023 and 2022, respectively.

ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results

Retrieved on: 
月曜日, 7月 31, 2023
Health, General Health, Capital expenditure, ASH, Marketing, MOH, European Medicines Agency, Survival, American Society of Clinical Oncology, György Enyedi (geographer), ESGO, Congress, Huadong Medicine, Patient, National Medical Products Administration, Spacecraft, European Hematology Association, Research, University Clinical Centre in Gdańsk, Mirvetuximab soravtansine, EMA, ADC, FDA, NMPA, Cancer, NSCLC, Acute myeloid leukemia, PROC, Ministry, PIN, ImmunoGen, MAA, Ovarian cancer, ORR, European Society of Gynaecological Oncology, Clinical trial, ASCO, AML, Azacitidine, Annual general meeting, EHA, BPDCN, Society, Food, Medicine, Vaccine, Pharmaceutical industry, Mobile phone

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.
  • Research and development expenses were $50.1 million for the quarter ended June 30, 2023 compared to $51.4 million for the quarter ended June 30, 2022.
  • Selling, general and administrative expenses were $36.4 million for the quarter ended June 30, 2023 compared to $23.8 million for the quarter ended June 30, 2022.
  • Net loss for the second quarter of 2023 was $4.2 million, or $0.02 per share, compared to a net loss of $62.0 million, or $0.24 per share, for the second quarter of 2022.

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results

Retrieved on: 
金曜日, 4月 28, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Biologics license application, Capital expenditure, Society, SGO, ASH, Senior, Progression-free survival, Marketing, European Medicines Agency, Survival, Clinical trial, Cancer, Gynecologic Oncology (journal), György Enyedi (geographer), Society of Gynecologic Oncology, NSCLC, Lung cancer, PFS, Mirvetuximab soravtansine, Gilead, Eli Lilly, EMA, Acute myeloid leukemia, PROC, AML, Azacitidine, PIN, Huadong Medicine, Pharmakon—Danish College of Pharmacy Practice, Patient, National Medical Products Administration, Annual general meeting, ImmunoGen, Vertex Pharmaceuticals, ADC, Spacecraft, MAA, Research, FDA, Ovarian cancer, LP, BLA, NMPA, Medicine, Vaccine, Management, Pharmaceutical industry, Mobile phone, Vertex

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
  • Research and development expenses rose to $51.6 million for the quarter ended March 31, 2023 compared to $44.3 million for the quarter ended March 31, 2022.
  • Selling, general and administrative expenses were $40.0 million for the quarter ended March 31, 2023 compared to $16.6 million for the quarter ended March 31, 2022.
  • ImmunoGen had $201.2 million in cash and cash equivalents as of March 31, 2023, compared with $275.1 million as of December 31, 2022.

ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results

Retrieved on: 
金曜日, 11月 4, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Society, Bevacizumab, Ovarian cancer, FDA, PIN, Zenith Contract Services, Research, ImmunoGen, U.S. Securities and Exchange Commission, Clinical trial, Lilly, Oncology, Capital expenditure, National Comprehensive Cancer Network, Society of Gynecologic Oncology, Program, ESGO, Venetoclax, Company, Congress, BLA, Carboplatin, ASH, Gynecologic Oncology (journal), BPDCN, Journal of the National Comprehensive Cancer Network, PDUFA, Hematology-Oncology and Stem Cell Transplantation Research Center, Security (finance), IMGN, Control, Patient, Cancer, ADC, Maintenance, Azacitidine, ESMO, European Society of Gynaecological Oncology, COVID-19, Annual general meeting, Novartis, SOHO, NCCN, SGO, Acute myeloid leukemia, Standard of care, Risk, AML, György Enyedi (geographer), Vaccine, Pharmaceutical industry, Medical imaging, Platinum, Cryptocurrency

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.
  • With an intense focus on execution, we are well positioned to transform ImmunoGen into a fully-integrated oncology company this year.
  • Total revenues were $15.4 million for the quarter ended September 30, 2022 compared to $9.2 million for the quarter ended September 30, 2021.
  • Operating expenses for the quarter ended September 30, 2022 were $92.8 million, compared with $43.4 million for the same quarter in 2021.

ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results

Retrieved on: 
金曜日, 5月 6, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, COVID-19, ASCO, American Society of Clinical Oncology, U.S. Securities and Exchange Commission, Society, Gynecologic Oncology (journal), Bevacizumab, PFS, Eli Lilly and Company, File, AML, IND, ImmunoGen, Venetoclax, Maintenance, Azacitidine, Carboplatin, Control, Food, Safety, Society of Gynecologic Oncology, Research, Patient, BLA, Security (finance), Acute myeloid leukemia, Program, ASH, FDA, Cancer, US Foods, Huadong Medicine, IMGN, György Enyedi (geographer), SGO, Capital expenditure, CMC, ID, PDUFA, Annual general meeting, Awareness, Priority review, Vaccine, Pharmaceutical industry, Medical imaging, Platinum, Risk management, Video game, Online gambling, Company, Lilly, BPDCN

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2022.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2022.
  • Total revenues were $38.1 million for the quarter ended March 31, 2022 compared to $15.7 million for the quarter ended March 31, 2021.
  • Operating expenses for the quarter ended March 31, 2022 were $60.9 million, compared with $44.6 million for the same quarter in 2021.
  • ImmunoGen had $437.7 million in cash and cash equivalents as of March 31, 2022, compared with $478.8 million as of December 31, 2021.

ImmunoGen Reports Recent Progress and 2021 Financial Results

Retrieved on: 
金曜日, 2月 25, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Head, Security (finance), ID, COVID-19, FACP, CMC, IND, Society of Gynecologic Oncology, Chemistry, Capital expenditure, Research, Society, Board, SGO, Medical Affairs Bureau, Azacitidine, AML, ImmunoGen, Initiate, Sale, Jazz Pharmaceuticals, Gynecologic Oncology (journal), U.S. Securities and Exchange Commission, Medicine, BLA, Food, György Enyedi (geographer), Leadership, Maintenance, Director, Ovarian cancer, Population, MPH, Bevacizumab, Eli Lilly and Company, US Foods, IMGN, Patient, Carboplatin, Control, Clinical trial, ASH, Venetoclax, FDA, Lilly, Cancer, Vaccine, Management, Pharmaceutical industry, Platinum, Risk management, Online gambling, Airline, Company, BPDCN, Huadong Medicine, MD

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2021.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2021.
  • Together with the appointment of key leadership positions and an oversubscribed follow-on offering in the fourth quarter, this progress positions us for success in 2022 and beyond.
  • Initiated accrual in PICCOLO, a single-arm study of mirvetuximab monotherapy in FR-high recurrent platinum-sensitive ovarian cancer.
  • ImmunoGen expects that its current cash, combined with anticipated product and collaboration revenues, will fund operations into 2024.

ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results

Retrieved on: 
金曜日, 10月 29, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, György Enyedi (geographer), Cancer, Control, Industry, Carboplatin, File, ADC, ImmunoGen, U.S. Securities and Exchange Commission, Patient, BLA, FDA, Private Securities Litigation Reform Act, Ovarian cancer, Genta (company), ASH, ID, BPDCN, Security (finance), Azacitidine, Annual report, Company, Clinical trial, Board, COVID-19, IND, AML, Research, ATM, Intellectual property, Capital expenditure, Sale, Director, Society, IMGN, Pharmaceutical industry, Fine chemical, Animal, Video game

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2021.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2021.
  • Revenues for the quarter ended September 30, 2021 were $9.2 million, compared with $18.2 million for the quarter ended September 30, 2020.
  • Revenues for the quarter ended September 30, 2021 also included recognition of an anticipated $2.5 million partner development milestone fee.
  • Operating expenses for the third quarter of 2021 were $43.4 million, compared with $34.9 million for the same quarter in 2020.